J.P. Morgan is out with its report today on Luminex LMNX, maintaining Neutral.
In its report, J.P. Morgan writes, "LMNX continues to trade at a premium valuation (on either P/Sales or P/E) to peers, and we see limited room for multiple expansion, with the potential for a slowdown in bulk purchases in 1H12."
J.P. Morgan maintains an $18 PT on LMNX.
Shares of LMNX closed Tuesday at $20.92, down 4.74% from Monday's close.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: Analyst ColorReiterationAnalyst RatingsHealth CareJ.P. MorganLife Sciences Tools & Services
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in